Hims & Hers: A Cartography of Consumption

by

The firm known as Hims & Hers – a designation which, were one to encounter it in a forgotten bestiary, might suggest a pair of mythical guardians – presents a curious case for the student of markets. It is not merely a purveyor of pharmaceuticals, but a constructor of desire, a cartographer of consumption. Its recent entanglement with Novo Nordisk, a dispute echoing the ancient conflicts over alchemical secrets, is less a threat than a symptom of its disruptive potential.

The Architecture of Access

To describe Hims & Hers as a ‘drug company’ is to diminish its ambition. It does, of course, deal in compounds intended to alter the human condition. But its innovation lies not in the creation of these substances, but in the architecture of access. It has bypassed the labyrinthine corridors of traditional healthcare, establishing a direct line to the consumer – a feat not unlike the legendary Library of Babel, attempting to contain all possible formulations of wellness within its digital walls.

The numbers, as always, offer a glimpse into this constructed reality. From a modest 300,000 subscribers in 2020, the firm has expanded to 2.5 million by 2025. Each subscriber represents not merely a transaction, but a node in an ever-expanding network of dependency. The recurrence of these purchases – a subscription, a commitment to ongoing acquisition – creates an annuity-like stream, a perpetual motion machine of revenue. One might envision it as a fractal, endlessly replicating its pattern of consumption.

This expansion is not random. It is a deliberate unfolding, a game plan predicated on broadening its offerings. As the brand gains traction, as the echo of its promises resonates within the marketplace, the potential for exponential growth increases. Each new subscriber adds not merely to the immediate revenue, but to the probability of further expansion – a phenomenon that, if unchecked, could reshape the landscape of healthcare itself.

The Shadow of Opposition

An investment of $5,000, at recent valuations, would secure approximately 333 shares. The price-to-earnings ratio, however, hovers around 29 – a figure that suggests a degree of speculative fervor. Value investors, those who seek refuge in the solidity of established returns, may find little to entice them here. Yet, for those attuned to the rhythms of growth, there is a compelling narrative to be found.

Loading widget...

The path forward, however, is not without its obstacles. Hims & Hers, in its attempt to disrupt the established order, has inevitably attracted opposition. The current dispute with Novo Nordisk – stemming from the firm’s replication of GLP-1 drugs during a period of supply constraint – is merely the most visible manifestation of this resistance. One suspects that other pharmaceutical giants, witnessing this challenge to their hegemony, are carefully studying the firm’s methods, preparing their own counter-strategies.

Novo Nordisk’s legal challenge, while likely to succeed in the short term, feels almost beside the point. The true story here is not about the legality of imitation, but about the power of direct access. Hims & Hers has tapped into a fundamental desire for convenience and control, creating a model that resonates deeply with its subscribers. Whether this model can withstand the inevitable onslaught of competition remains to be seen, but its initial success suggests that the firm has stumbled upon a potent, perhaps even transformative, force.

Read More

2026-02-27 12:52